Summary

Eligibility
for people ages 50-80 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.

Official Title

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)

Keywords

Progressive Supranuclear Palsy, Disease progression, FNP-223, Paralysis

Eligibility

Locations

  • UCSF Weill Institute for Neurosciences accepting new patients
    San Francisco California 94158 United States
  • The Neurology Center of Southern California - Carlsbad accepting new patients
    Carlsbad California 92011 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ferrer Internacional S.A.
ID
NCT06355531
Phase
Phase 2 Progressive Supranuclear Palsy Research Study
Study Type
Interventional
Participants
Expecting 220 study participants
Last Updated